Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Phase 2a Study To Assess the Safety, Tolerability and Prophylactic Antiviral Activity of Neumifil Against Influenza, Via a Human Viral Challenge Model in Healthy Adult Participants

Next Previous
Search
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Phase 2a Study To Assess the Safety, Tolerability and Prophylactic Antiviral Activity of Neumifil Against Influenza, Via a Human Viral Challenge Model in Healthy Adult Participants

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 30 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Neumifil (Primary)
  • Indications Influenza virus infections
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Pneumagen

    • Most Recent Events

    • 23 May 2024 Results published in a Pneumagen media release.
    • 23 May 2024 According to a Pneumagen media release, results from Phase 2, proof-of-concept, Controlled Human Infection Model (CHIM) study in which healthy volunteers were challenged with influenza virus following administration of Neumifil. These data were featured during an oral presentation at the American Thoracic Society (ATS) in San Diego on 21st May.
    • 22 May 2024 Results assessing the safety, tolerability, and prophylactic antiviral activity of Neumifil , presented at the 120th International Conference of the American Thoracic Society

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top